[Molecular-targeted therapy]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Molecular-targeted therapy offers a more precise approach to cancer treatment compared to traditional chemotherapy.
• The development of targeted agents aims to inhibit specific molecular pathways driving tumor growth and progression.

Purpose of the Study:

• To review the concept and current status of molecular-targeted therapy for lung cancer.
• To highlight the progress of specific targeted agents, particularly epidermal growth factor receptor inhibitors.
• To discuss the implications for future research and clinical application in lung cancer treatment.

Main Methods:

• Literature review of preclinical and clinical studies on molecular-targeted therapy in lung cancer.
• Analysis of data from phase II clinical trials of epidermal growth factor receptor inhibitors.
• Synthesis of information on the mechanisms of action and clinical efficacy of targeted agents.

Main Results:

• Molecular-targeted therapy represents a significant advancement in lung cancer treatment.
• Epidermal growth factor receptor inhibitors demonstrate promising antitumor activity in phase II trials, especially in cisplatin-resistant non-small cell lung cancer.
• These targeted agents offer a potential therapeutic option for patients with specific molecular alterations.

Conclusions:

• Molecular-targeted therapy, particularly with epidermal growth factor receptor inhibitors, holds significant potential for improving outcomes in non-small cell lung cancer.
• Further rigorous clinical evaluation of these agents is crucial.
• Enhanced collaboration between clinical oncologists and basic researchers is essential for optimizing the development and application of molecular-targeted therapies.